Antiproliferation and Apoptosis Induction in Colorectal Cancer Cells by Goniothalamin

• Published in: Journal of the Medical Association of Thailand Vol. 98 Suppl 9; p. S146
• Main Authors: Sophonnithiprasert, Thanet, Mahabusarakam, Wilawan, Nakamura, Yukio, Watanapokasin, Ramida
• Format: Journal Article
• Language: English
• Published: Thailand 01-10-2015
• Subjects: Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; Colorectal Neoplasms - drug therapy; Humans; Pyrones - pharmacology
• ISSN: 0125-2208

To investigate the effect of goniothalamin on antiproliferation and apoptosis induction in three types of colorectal cancer cells.
Colorectal cancer is the third of the twentieth most commonly diagnosed cancer. Different types of colorectal cancer cells differ in genotype and characteristics leading to different responses to anticancer drugs. Therefore, finding new anticancer compound for the colorectal cancer cells is necessary.
Antiproliferative response of goniothalamin on three colorectal cancer cell lines including Colo 205, SW480, and LoVo were determined by MTT assay. The antiproliferative response at different time and dose was also observed. Apoptosis induction by goniothalamin was observed in all three cell-lines via morphological changes and nuclear condensation by Hoechst33342 staining.
Goniothalamin showed different antiproliferative response on Colo 205, SW480, and Lo Vo cells at the IC50 value is 9.86 ± 0.38 µM, 22.00 ± 4.40 µM, and 65.25 ± 1.85 µM respectively. In addition, the antiproliferative response of goniothalamin was a time- and dose-dependent manner Apoptosis morphological changes and nuclear condensation were clearly observed in Colo 205, SW480 and LoVo cells treated with 10 µM, 25 µM, and 50 µM goniothalamin, respectively.
Goniothalamin showed antiproliferation and apoptosis induction in colorectal cancer cells with different sensitivity depending on cell type. Investigation of mechanisms underlying apoptosis and its potential use for colorectal cancer treatment should be further studied.